• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

与玻璃体内抗血管内皮生长因子治疗相关的疑似化脓性肉芽肿。

Presumed pyogenic granuloma associated with intravitreal anti-vascular endothelial growth factor therapy.

作者信息

Jung Jesse J, Della Torre Kara E, Fell Millie R, Teng Christopher C, Freund K Bailey

机构信息

Department of Ophthalmology, New York University School of Medicine, New York, NY, USA.

出版信息

Open Ophthalmol J. 2011;5:59-62. doi: 10.2174/1874364101105010059. Epub 2011 Dec 19.

DOI:10.2174/1874364101105010059
PMID:22216076
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3249641/
Abstract

To report a case of a presumed pyogenic granuloma at the site of multiple intravitreal anti-Vascular Endothelial Growth Factor (VEGF) injections. Intravitreal anti-VEGF injections can be complicated by a localized reaction of the conjunctiva.

摘要

报告1例在多次玻璃体内注射抗血管内皮生长因子（VEGF）药物部位出现的疑似化脓性肉芽肿病例。玻璃体内注射抗VEGF药物可能并发结膜局部反应。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9260/3249641/6dfcb5586d10/TOOPHTJ-5-59_F3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9260/3249641/f8b71f58f49c/TOOPHTJ-5-59_F1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9260/3249641/317a413c4d06/TOOPHTJ-5-59_F2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9260/3249641/6dfcb5586d10/TOOPHTJ-5-59_F3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9260/3249641/f8b71f58f49c/TOOPHTJ-5-59_F1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9260/3249641/317a413c4d06/TOOPHTJ-5-59_F2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9260/3249641/6dfcb5586d10/TOOPHTJ-5-59_F3.jpg

相似文献

1
Presumed pyogenic granuloma associated with intravitreal anti-vascular endothelial growth factor therapy.与玻璃体内抗血管内皮生长因子治疗相关的疑似化脓性肉芽肿。
Open Ophthalmol J. 2011;5:59-62. doi: 10.2174/1874364101105010059. Epub 2011 Dec 19.
2
Conjunctival pyogenic granuloma associated with intravitreal bevacizumab injection.
Retin Cases Brief Rep. 2013 Summer;7(3):291-3. doi: 10.1097/ICB.0b013e31828ef010.
3
Vitreomacular Interface after Anti-Vascular Endothelial Growth Factor Injections in Neovascular Age-Related Macular Degeneration.抗血管内皮生长因子注射治疗新生血管性年龄相关性黄斑变性后的玻璃体内黄斑界面。
Ophthalmology. 2015 Aug;122(8):1569-72. doi: 10.1016/j.ophtha.2015.04.028. Epub 2015 May 30.
4
Severe Ocular Inflammation Following Ranibizumab or Aflibercept Injections for Age-Related Macular Degeneration: A Retrospective Claims Database Analysis.雷珠单抗或阿柏西普注射治疗年龄相关性黄斑变性后发生的严重眼部炎症：一项回顾性索赔数据库分析
Ophthalmic Epidemiol. 2016;23(2):71-9. doi: 10.3109/09286586.2015.1090004. Epub 2016 Feb 8.
5
Systemic levels of vascular endothelial growth factor before and after intravitreal injection of aflibercept or ranibizumab in patients with age-related macular degeneration: a randomised, prospective trial.玻璃体内注射阿柏西普或雷珠单抗前后年龄相关性黄斑变性患者血管内皮生长因子的全身水平：一项随机、前瞻性试验。
Acta Ophthalmol. 2015 Mar;93(2):e154-9. doi: 10.1111/aos.12604. Epub 2014 Dec 8.
6
Hypertensive cerebral hemorrhage with undetectable plasma vascular endothelial growth factor levels in a patient receiving intravitreal injection of aflibercept for bilateral diabetic macular edema: a case report.一名接受玻璃体内注射阿柏西普治疗双侧糖尿病性黄斑水肿的患者发生高血压性脑出血且血浆血管内皮生长因子水平检测不到：病例报告
J Med Case Rep. 2021 Jul 27;15(1):403. doi: 10.1186/s13256-021-02983-3.
7
A comparison of responses to intravitreal bevacizumab, ranibizumab, or aflibercept injections for neovascular age-related macular degeneration.玻璃体内注射贝伐单抗、雷珠单抗或阿柏西普治疗新生血管性年龄相关性黄斑变性的疗效比较。
Int Ophthalmol. 2017 Oct;37(5):1205-1214. doi: 10.1007/s10792-016-0391-4. Epub 2016 Nov 8.
8
Arteriosclerotic Changes after Intravitreal Injections of Anti-Vascular Endothelial Growth Factor Drugs in Patients with Exudative Age-Related Macular Degeneration.湿性年龄相关性黄斑变性患者玻璃体内注射抗血管内皮生长因子药物后的动脉硬化改变
Ophthalmologica. 2016;235(4):225-32. doi: 10.1159/000445388. Epub 2016 Apr 16.
9
A Mechanistic Model of the Intravitreal Pharmacokinetics of Large Molecules and the Pharmacodynamic Suppression of Ocular Vascular Endothelial Growth Factor Levels by Ranibizumab in Patients with Neovascular Age-Related Macular Degeneration.新生血管性年龄相关性黄斑变性患者玻璃体内大分子药物动力学的机制模型及雷珠单抗对眼血管内皮生长因子水平的药效学抑制作用
Mol Pharm. 2016 Sep 6;13(9):2941-50. doi: 10.1021/acs.molpharmaceut.5b00849. Epub 2016 Jan 14.
10
Endophthalmitis Rates after Bilateral Same-Day Intravitreal Anti-Vascular Endothelial Growth Factor Injections.双眼同一天接受抗血管内皮生长因子玻璃体内注射后的眼内炎发生率。
Am J Ophthalmol. 2018 Oct;194:1-6. doi: 10.1016/j.ajo.2018.06.022. Epub 2018 Jul 6.

引用本文的文献

1
Anterior segment optical coherence tomography in ocular surface tumours and simulating lesions.眼前节光学相干断层扫描在眼表肿瘤和模拟病变中的应用。
Eye (Lond). 2023 Apr;37(5):925-937. doi: 10.1038/s41433-022-02339-1. Epub 2022 Dec 13.
2
Systemic Drug-induced Chronic Paronychia and Periungual Pyogenic Granuloma.系统性药物性慢性甲沟炎和甲周化脓性肉芽肿。
Indian Dermatol Online J. 2018 Sep-Oct;9(5):293-298. doi: 10.4103/idoj.IDOJ_133_18.

本文引用的文献

1
Injection site ischemia and inflammation after intravitreal bevacizumab.玻璃体内注射贝伐单抗后的注射部位缺血与炎症。
Retin Cases Brief Rep. 2010 Fall;4(4):294-6. doi: 10.1097/ICB.0b013e3181aff491.
2
Sustained increased intraocular pressure related to intravitreal antivascular endothelial growth factor therapy for neovascular age-related macular degeneration.与新生血管性年龄相关性黄斑变性的玻璃体内抗血管内皮生长因子治疗相关的持续性眼压升高。
J Glaucoma. 2012 Apr-May;21(4):241-7. doi: 10.1097/IJG.0b013e31820d7d19.
3
Short-term effect of intravitreal injection of Ranibizumab (Lucentis) on intraocular pressure.
雷珠单抗（Lucentis）玻璃体内注射对眼内压的短期影响。
J Glaucoma. 2009 Dec;18(9):658-61. doi: 10.1097/IJG.0b013e31819c4893.
4
Pyogenic granuloma after retinal detachment surgery with scleral buckle: case report.巩膜扣带术视网膜脱离手术后的化脓性肉芽肿：病例报告
Arq Bras Oftalmol. 2009 Jul-Aug;72(4):543-4. doi: 10.1590/s0004-27492009000400021.
5
Safety and efficacy of intravitreal anti-VEGF injections for age-related macular degeneration.玻璃体内注射抗血管内皮生长因子药物治疗年龄相关性黄斑变性的安全性和有效性
Curr Opin Ophthalmol. 2009 May;20(3):223-5. doi: 10.1097/ICU.0b013e328329b656.
6
Safety of repeat intravitreal injections of bevacizumab versus ranibizumab: our experience after 2,000 injections.玻璃体内重复注射贝伐单抗与雷珠单抗的安全性：2000次注射后的经验
Retina. 2009 Mar;29(3):313-8. doi: 10.1097/IAE.0b013e31819a5f98.
7
Intravitreal silicone oil droplets following pegaptanib injection.注射培加他尼后玻璃体内的硅油滴
Acta Ophthalmol. 2010 Mar;88(2):e44-5. doi: 10.1111/j.1755-3768.2008.01336.x. Epub 2008 Oct 24.
8
Intravitreal silicone oil droplets after intravitreal drug injections.玻璃体内注射药物后出现的玻璃体内硅油滴。
Retina. 2008 Jul-Aug;28(7):996-1001. doi: 10.1097/IAE.0b013e31816c6868.
9
Intravitreal ranibizumab and bevacizumab: a review of risk.玻璃体内注射雷珠单抗和贝伐单抗：风险综述
Semin Ophthalmol. 2007 Jul-Sep;22(3):201-4. doi: 10.1080/08820530701543024.
10
Ranibizumab for neovascular age-related macular degeneration.雷珠单抗用于治疗新生血管性年龄相关性黄斑变性。
N Engl J Med. 2006 Oct 5;355(14):1419-31. doi: 10.1056/NEJMoa054481.